Core Viewpoint - Suzhou Rebio Biotechnology Co., Ltd. is attempting to re-enter the capital market by submitting a prospectus to the Hong Kong Stock Exchange after failing to launch on the STAR Market four years ago, despite being one of the earliest companies in China to focus on small RNA drugs [1][3] Group 1: Company Overview - Founded in 2007, Rebio focuses on developing innovative therapies for cardiovascular, metabolic, renal, and liver diseases, particularly siRNA therapies [1] - The company has six self-developed drug pipelines currently in clinical trials, with four in Phase II and one in Phase III [1] Group 2: R&D Progress and Challenges - The fastest progressing pipeline, RBD1007, completed international Phase II/III research data analysis in 2021 but has not yet resulted in a marketable product [3] - Previous key pipelines RBD4988 and RBD1006 are not mentioned in the latest prospectus, indicating they may have "failed" [3] - The new core pipelines include RBD4059 for thrombotic diseases, RBD5044 for hypertriglyceridemia, and RBD1016 for chronic hepatitis B and D, all currently in Phase II, facing significant uncertainty regarding clinical efficacy and market viability [3][4] Group 3: Market Competition - Rebio's R&D progress is lagging behind competitors, with its core product RBD4059 in Phase II while similar products from Novartis have reached Phase III [4] - Ionis's APOC3-targeted drug has already been launched, raising doubts about Rebio's "Best-in-Class" potential for RBD5044, which has yet to release clinical data [4] Group 4: Financial Performance and Valuation - Rebio's valuation has fluctuated significantly, from 456 million yuan in 2015 to 3.15 billion yuan in 2020, peaking at 4.87 billion yuan in 2024, but has since dropped back to 3.58 billion yuan, equivalent to its valuation five years ago [5][6] - In 2023, the company reported revenue of only 44,000 yuan, which is expected to rise to 143 million yuan in 2024 through a partnership with Boehringer Ingelheim, but 90% of this revenue relies on a single partner, indicating a fragile income structure [6] - Total R&D expenses for 2023 and 2024 are projected to be 590 million yuan, with cumulative net losses reaching 718 million yuan, and cash reserves expected to be only 168 million yuan by the end of 2024, against interest-bearing loans of 399 million yuan, putting significant pressure on the company's cash flow [6] Group 5: Strategic Partnerships and Risks - Rebio has frequently utilized licensing agreements to alleviate financial pressure, including a deal with Boehringer Ingelheim worth over $2 billion and a licensing agreement for RBD7022 in Greater China for over 700 million yuan [7] - While these partnerships provide short-term cash flow, they may compromise future value, as the agreements do not clearly define patent ownership improvements, potentially limiting Rebio's share in future developments based on its core delivery technology [7]

Group 1: A+H Listing Expansion - The Hong Kong stock market is experiencing a surge in listing applications, with 14 companies submitting applications between April 25 and 28, including industry leaders seeking A+H listings [1] - Three Squirrels aims to become the first A+H snack brand, reporting a projected revenue of 10.622 billion yuan and a net profit of 408 million yuan for 2024, with 70% of revenue coming from online channels [2] - JA Solar has submitted its application for an A+H listing, reporting a projected revenue of 70.121 billion yuan for 2024, but facing a net loss of 4.656 billion yuan due to asset impairment losses [3][4] - Seres has successfully turned a profit in 2024, with a revenue of 1.45176 billion yuan and a net profit of 5.946 billion yuan, driven by increased sales of electric vehicles [5][6] Group 2: Companies Transitioning to Hong Kong - Rebio Biotech has submitted its application to the Hong Kong Stock Exchange after previously attempting to list on the A-share market, reporting a net loss of 437.3 million yuan in 2023 [8][9] - Daji Group, which focuses on innovative radiation surgery solutions, has also shifted its listing application to Hong Kong after previously applying for the Sci-Tech Innovation Board [10][11] - Hongyeji has submitted its application to the Hong Kong Stock Exchange after previously attempting to list on the Shenzhen Stock Exchange, reporting revenues of approximately 1.228 billion yuan in 2022 [12]

RBD4059为全球首款且临床开发进展最快的抗血栓siRNA药物。 本文为IPO早知道原创 作者｜罗宾 瑞博生物目前拥有 6 款自研管线处于临床试验阶段，涉及 7 种适应症，其中 4 款处于 2 期临床试验 中，一款已进入 III 期临床试验。公司还有 20 个计划推进到临床开发阶段的临床前项目。 来源：公司招股书 核心产品 RBD4059 （靶向 FXI 的 siRNA ）为全球首款、也是临床开发进展最快的用于治疗血栓性 疾病的 siRNA 药物 ，通过选择性抑制 FXI ， RBD4059 可在不显著增加出血风险（传统抗凝剂的常 见局限性）的情况下降低血栓形成的风险，同时以低频率的给药产生持久的疗效，提高患者的依从 性。 同时，公司还在推进两款关键产品 RBD5044 及 RBD1016 。 RBD5044 是全球第二个进入临床开发 的靶向 APOC3 的 siRNA 。 APOC3 是一种在脂质代谢中起关键作用的蛋白质。而 RBD1016 凭借 其对 HBsAg 的强效和持久作用，是未来实现 CHB 功能性治愈的联合方法的重要支柱疗法，及治疗 CHD 的领先 siRNA 候选药物。 公司经过近二十年的专 ...

Group 1: Company Overview - Suzhou Ribo BioTechnology Co., Ltd. (Ribo Bio) submitted its main board listing application to the Hong Kong Stock Exchange on April 25, marking a significant capital move after the termination of its Sci-Tech Innovation Board application in 2021 [1] - Founded in 2007, Ribo Bio is a global leader in the research and development of small nucleic acid drugs, particularly focusing on siRNA therapies, aiming to innovate treatment methods for cardiovascular, metabolic, kidney, and liver diseases [1][2] - The company has established a self-developed technology platform that covers all key aspects of small nucleic acid drug development, from drug delivery to chemical modification and multi-target drug design, supporting the entire lifecycle from early research to commercialization [1] Group 2: Market and Industry Trends - The small nucleic acid drug industry is rapidly evolving, with increasing competition from multinational companies and leading biotech firms developing similar or competing siRNA drugs [3] - The global small nucleic acid drug market is projected to grow from $2.7 billion in 2019 to $4.6 billion in 2023, with a compound annual growth rate (CAGR) of 14.3%, and is expected to reach $46.7 billion by 2033 at a CAGR of 26.1% [4] Group 3: Product Pipeline and Development - Ribo Bio has one of the largest siRNA drug pipelines globally, with six self-developed drug assets in clinical trials targeting seven indications related to cardiovascular, metabolic, kidney, and liver diseases, four of which are in Phase 2 trials [4] - The core product RBD4059, targeting FXI, is the world's first siRNA drug for treating thrombotic diseases, which is a leading cause of death globally, claiming over 10 million lives annually [6] - Ribo Bio is also advancing two key products, RBD5044 and RBD1016, which are significant in the treatment of lipid metabolism disorders and chronic hepatitis B, respectively [6] Group 4: Financial Performance - As of the end of 2023 and 2024, Ribo Bio reported net losses of RMB 437.3 million and RMB 281.5 million, respectively, with no revenue from commercial product sales [7][8] - The company anticipates substantial R&D expenditures as it progresses its clinical development plans, with R&D costs constituting 79.5% and 75.0% of total operating expenses for 2023 and 2024, respectively [9][10]

Core Viewpoint - Suzhou Ribo BioTechnology Co., Ltd. has submitted its A1 listing application to the Hong Kong Stock Exchange, marking a significant step in its development as a pioneer in RNA interference (RNAi) technology and small nucleic acid drug commercialization [1] Group 1: Company Overview - Ribo Bio was established in 2007 and is one of the earliest pioneers in the field of RNAi technology [1] - The company has received strategic investments from several well-known institutions, including Junlian Capital and Guotou Innovation [1] Group 2: Market Potential - The global small nucleic acid drug market has grown from $2.7 billion in 2019 to $4.6 billion in 2023, with a compound annual growth rate (CAGR) of 14.3%, and is expected to reach $46.7 billion by 2033 [2] - siRNA drugs are seen as a disruptive innovation in the pharmaceutical industry, with clinical success rates improving from below 10% for traditional drugs to over 60% for siRNA [2] Group 3: Product Pipeline - Ribo Bio currently has six self-developed siRNA drugs in clinical trials, with four in Phase II trials and over 20 preclinical assets in development [4] - The key product RBD4059 is the first siRNA drug for thrombotic diseases and is progressing rapidly in clinical trials [6] - RBD5044 targets high triglycerides and is the second siRNA drug targeting APOC3 to enter clinical development [7] - RBD7022 is a promising candidate for treating high cholesterol, showing comparable LDL-C reduction to the approved drug Inclisiran [8] - RBD1016 is a key candidate for chronic hepatitis B treatment, showing good safety and efficacy in early trials [9] Group 4: Technological Advancements - Ribo Bio has developed the RiboGalSTAR™ liver-targeting delivery platform, which has shown strong efficacy and safety in clinical studies [12] - The company has established a comprehensive R&D network with nearly 300 researchers and has a production line compliant with EU GMP standards [11] Group 5: Strategic Collaborations - Ribo Bio has entered a significant collaboration with Boehringer Ingelheim, valued at over $2 billion, marking a notable recognition of its RNAi technology platform [13] - The company aims to leverage its innovative capabilities and global partnerships to enhance its position in the small nucleic acid drug market [13]